Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors

(2019) Albiruni R. Abdul Razak et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors

(2016) A. Razak et al.   EUROPEAN JOURNAL OF CANCER

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

(2016) A Quintás-Cardama et al.   LEUKEMIA

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

(2015) Hua Zhong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Role of p53 in Cell Death and Human Cancers

(2011) Toshinori Ozaki et al.   Cancers

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design

(2008) Jeffrey M. Skolnik et al.   JOURNAL OF CLINICAL ONCOLOGY